In East Asia, especially China, where chronic hepatitis B virus (HBV) infection is an important etiological factor of HCC and where the disease is different from that in other countries [1, 17], the efficacy of lenvatinib plus PD-1 inhibitor combination therapy is unclear. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.